Equities
  • Price (USD)0.2818
  • Today's Change-0.012 / -4.08%
  • Shares traded95.88k
  • 1 Year change-86.52%
  • Beta2.7534
Data delayed at least 15 minutes, as of Sep 20 2024 20:09 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. It is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

  • Revenue in USD (TTM)2.22m
  • Net income in USD-37.49m
  • Incorporated2018
  • Employees102.00
  • Location
    Renalytix PLCFinsgate, 5-7 Cranwood StreetLONDON EC1V 9EEUnited KingdomGBR
  • Phone+44 292 071 0570
  • Websitehttps://renalytix.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
LiveCare Inc0.00-2.34m15.26m----6.47-----0.1411-0.14110.000.04630.00-------424.83---550.62-------------8.180.1888-------344.86------
Cutera Inc169.19m-148.97m15.50m430.00------0.0916-7.46-7.468.46-10.730.45722.083.86393,460.50-40.25-22.00-51.64-30.728.1847.63-88.05-27.242.17-31.342.05---15.865.47-97.76--85.87--
Innovative Eyewear Inc1.53m-7.86m15.53m11.00--2.06--10.15-11.01-11.012.054.810.17791.9715.91139,070.90-91.45---96.06---2.46---514.10--12.85--0.00--74.67---17.28------
BioRegenx Inc634.81k-727.95k17.12m10.00--1.01--26.97-0.001-0.0010.00160.01780.0617----63,481.00-7.07---8.46--74.90---114.67--0.1547-8.800.0977---47.25---629.37------
PAVmed Inc3.83m-67.35m17.17m107.00------4.48-8.17-8.170.4595-7.740.0823--29.4535,785.05-155.93-154.56---1,152.82-77.59---1,895.64-8,764.890.5529-8.161.74--550.40--25.76--55.51--
Beyond Air Inc1.78m-58.35m17.78m107.00--1.09--9.97-1.65-1.650.04850.35140.02981.706.8716,663.55-104.22-78.25-137.64-99.91-78.30---3,493.78-6,152.992.42-38.110.4666-----31.57-7.93--152.05--
Spectral AI Inc22.53m-20.24m19.01m78.00------0.8439-1.48-1.481.55-0.24221.68--11.54288,859.00-150.54---954.46--45.12---89.85--0.7066--2.14---28.82---616.14------
Neuraxis Inc2.27m-15.26m20.05m19.00------8.84-3.09-3.090.4039-0.76861.096.6311.80119,318.90-731.17------87.29---672.94--0.2724-19.01-----8.37---163.78------
SeaStar Medical Holding Corp0.00-33.23m20.79m12.00---------21.41-21.410.00-2.140.00----0.00-1,145.80-----------------9.51---------115.19------
Renalytix PLC (ADR)2.22m-37.49m20.94m102.00------9.43-0.7843-0.78430.0463-0.18530.0915--3.41---154.36-102.16-396.70-124.78-1.58---1,687.80-2,268.11---8.74----14.58---0.7311------
Inspira Technologies Oxy BHN Ltd0.00-11.29m23.23m37.00--3.44-----0.9549-0.95490.000.36660.00----0.00-88.60-114.98-108.36-159.56------------0.00------24.64------
IR-Med Inc0.00-3.47m24.05m6.00--66.22-----0.0499-0.04990.000.00510.00----0.00-197.95---273.36--------------0.3019-------3.70------
Orgenesis Inc662.00k-29.02m25.81m146.00------38.99-0.8684-0.86840.02-0.33030.027278.295.384,534.25-122.18---1,312.10---101.06---4,489.28--0.0741-5.85-----98.53-50.94-271.82---17.71--
Femasys Inc950.09k-16.69m26.01m32.00--2.31--27.38-0.8468-0.84680.04720.50600.05490.34387.6529,690.31-96.51---108.58--65.67---1,756.83--5.93-77.250.2972---11.13---25.04------
Meihua International Medical Tech Co Ltd97.10m11.63m26.22m617.002.120.16852.170.2700.48560.48564.066.110.578846.661.31157,372.606.9112.268.1315.0534.1938.1411.9415.475.21--0.04750.00-6.055.1086.22-5.56-9.16--
Data as of Sep 20 2024. Currency figures normalised to Renalytix PLC's reporting currency: US Dollar USD

Institutional shareholders

8.91%Per cent of shares held by top holders
HolderShares% Held
Jefferson River Capital LLCas of 19 Mar 20244.27m5.14%
Pinnacle Associates Ltd.as of 30 Jun 2024815.43k0.98%
Stifel Nicolaus & Co., Inc. (Investment Management)as of 30 Jun 2024560.00k0.68%
Levin Capital Strategies LPas of 30 Jun 2024555.00k0.67%
Tejara Capital Ltd.as of 30 Jun 2024500.39k0.60%
Corient Private Wealth LLCas of 30 Jun 2024335.51k0.40%
Nantahala Capital Management LLCas of 30 Jun 2024117.64k0.14%
Cantor Fitzgerald & Co.as of 30 Jun 2024115.00k0.14%
Wealth Enhancement Advisory Services LLCas of 30 Jun 202463.74k0.08%
Traynor Capital Management, Inc.as of 30 Jun 202460.00k0.07%
More ▼
Data from 10 Apr 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.